Adrenocortical carcinoma: Clinical presentation, outcomes of treatment and survival analysis from a 15-year experience
Completed
- Conditions
- ACC patients whounderwent surgical extirpation.Adrenocortical carcinoma, Surgery, Chemotherapy, Mitotane, Survival, Prognosis
- Registration Number
- TCTR20220614002
- Lead Sponsor
- Division of Urology, Department of Surgery
- Brief Summary
The median age was 51 years with females predominant. The median tumor size was 8.3 cm. 52.2% was in stage 2. Adjuvant therapies were required in 47.7% of patients. 34.8% were death. The 1,2,5-year overall survival were 78.3%, 73.9%, and 65.2%. The ENSAT stage 3-4 (HR 1.61,95%CI 1.16-21.5, p 0.03), nodal metastasis (HR 2.11 95%CI 1.36-50.26; p 0.02), distant metastasis (HR 1.75; 95%CI 1.16-28.62; p 0.03) and NLR above 5 (HR 2.66; 95%CI 1.74-116.81; p 0.01) were significant associated with disease mortality.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
ACC patients who
underwent surgical extirpation in King Chulalongkorn Memorial Hospital between January 2005 and December
2020.
Exclusion Criteria
Age under 18-year-old
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival at 12, 24, 60 months Kaplan-Meier Curve
- Secondary Outcome Measures
Name Time Method Prognostic factors none Cox-regression analysis